Intestinal neuroendocrine neoplasm
MONDO:0002883A neoplasm with neuroendocrine differentiation that arises from the small or large intestine. It includes well differentiated neuroendocrine tumors (low and intermediate grade) and poorly differentiated neuroendocrine carcinomas (high grade).
Also known as: intestinal neuroendocrine neoplasm, intestine NET, intestine neuroendocrine neoplasm, intestine neuroendocrine tumor, intestine neuroendocrine tumor, well differentiated, low or intermediate grade, intestine neuroendocrine tumour, neuroendocrine neoplasm of intestine, neuroendocrine neoplasm of the intestine
1483 clinical trials for this condition and its sub-types, 7 tagged with Intestinal neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Intestinal neuroendocrine neoplasm
-
Small intestine neuroendocrine neoplasm 0 trials · 9 incl. sub-types
3 sub-types
- Small intestine neuroendocrine tumor, well differentiated, low or intermediate grade 4 trials · 9 incl. sub-types Sub-types →
- Duodenal neuroendocrine neoplasm 0 trials Sub-types →
- Hereditary neuroendocrine tumor of small intestine 0 trials
-
Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types
2 sub-types
- Small intestinal neuroendocrine tumor G1 3 trials · 5 incl. sub-types Sub-types →
- Colorectal neuroendocrine tumor G1 1 trial · 4 incl. sub-types Sub-types →
-
Rectum neuroendocrine neoplasm 3 trials · 6 incl. sub-types
2 sub-types
- Rectal neuroendocrine tumor 3 trials · 4 incl. sub-types Sub-types →
- Anal canal neuroendocrine neoplasm 1 trial Sub-types →
-
Colon neuroendocrine neoplasm 0 trials · 5 incl. sub-types
3 sub-types
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
- Appendix neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Colon small cell neuroendocrine carcinoma 0 trials
Most studied deeper sub-types
-
Can spacing out radioactive drug doses reduce side effects in neuroendocrine tumors?
Disease control Recruiting nowThis study compares two schedules of the radioactive drug Lu177-Dotatate in 166 people with slow-growing midgut neuroendocrine tumors. One group gets the drug every 8 weeks (standard), the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-r…
Phase 3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Blood test may predict who benefits from targeted radiation therapy
Knowledge-focused Recruiting nowThis study looks at whether an inflammation-based score (using CRP and albumin levels) can predict how well patients with advanced intestinal neuroendocrine tumors respond to Lu-177 oxodotreotide therapy. Researchers will follow 150 patients for 36 months, collecting blood sample…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
14,000-Person study hunts for hidden triggers of rare tumors
Knowledge-focused Recruiting nowThis study aims to find out what factors might increase the risk of developing neuroendocrine tumors, a rare type of cancer. Researchers will analyze health records from over 14,000 people in Bavaria, Germany, looking at things like smoking, diabetes, and even depression. The goa…
Sponsor: Bavarian Cancer Registry • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC